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VALIDATION OF THE CHILDHOOD HEALTH ASSESSMENT
QUESTIONNAIRE (CHAQ) IN HUNTER SYNDROME
Tran KT1, Gold KF1, Stephens JM1, Kimura A2, Muenzer J3, Singh G4
1Abt Associates Inc, Bethesda, MD, USA; 2Transkaryotic Therapies Inc,
Cambridge, MA, USA; 3University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA; 4Stanford University, Palo Alto, CA, USA
OBJECTIVES: Mucopolysaccharidosis II (MPS II; Hunter syn-
drome) is a rare lysosomal storage disorder that leads to severe
functional declines in childhood and adolescence. Because no
disease-speciﬁc instruments currently exist for MPS II, this study
sought to conﬁrm the previously established psychometric prop-
erties of the CHAQ in this disease population. METHODS: All
twelve families participating in a Phase I/II enzyme replacement
therapy trial for MPS II agreed to participate in the IRB-
approved CHAQ conﬁrmatory validation study. Assessments
were completed during regular twice-monthly study visits. Only
patients 12 years and older completed the instrument although
all parents were asked to complete the questionnaire as a proxy
responder. Face validity, internal reliability, domain intercorrela-
tion coefﬁcients, parent-child correlations, and test-retest relia-
bility were assessed on the overall CHAQ disability index.
RESULTS: Nine patients (mean age 18.0 ± 4.3 years) and one
parent per child completed the CHAQ; three additional patients
(mean age 9.7 ± 1.5 years) had parent-reported assessments only
due to age limitations. The instrument showed good internal reli-
ability (Cronbach’s alpha = 0.86 [parents] and 0.83 [patients])
and good reproducibility in a test-retest over a 3-week period
(Spearman correlation coefﬁcient = 0.81, p = 0.0014 [parent];
0.94, p = 0.0002 [patient]). Parent-child correlation was moder-
ately weak at 0.38 (p = 0.317), a divergence commonly seen in
child/adolescent outcome measurements. Intercorrelation coefﬁ-
cients of each domain with the overall disability index were in
the moderate range (mean rs = 0.6 for parents, rs = 0.5 for
patient). Although face validity was acceptable, the CHAQ still
did not completely address certain functional challenges speciﬁc
to MPS II. CONCLUSION: The psychometric properties of the
CHAQ appear acceptable in measuring general disability and
functional status in MPS II. Further assessment of its sensitivity
and discriminant validity are needed as part of ongoing clinical
trials. Development of a disease-speciﬁc instrument appears war-
ranted given the unique functional challenges of patients with
MPS II.
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OBJECTIVES: To develop and pilot-test a new instrument to
assess physical functioning in children with Mucopolysacchari-
dosis II (MPS II; Hunter syndrome [HS]), a rare genetic, lysoso-
mal storage disease. METHODS: The survey item pool was
generated by: 1) thorough literature review to identify relevant
domains and questions; 2) consultation with expert clinicians
knowledgeable about MPS II; 3) identiﬁcation of indicators spe-
ciﬁc to MPS II not covered by existing instruments, and 4) input
from families affected by MPS II. Following IRB approval, the
item pool was tested in MPS II patients and their families attend-
ing the 2003 Annual MPS Society Family Conference. Data were
obtained via structured feedback forms completed during face-
to-face interviews. Inter-item correlations within each domain
were tested for internal reliability. Results were used to modify
items to create a ﬁnalized instrument, the HS-FOCUS.
RESULTS: Two versions of the HS-FOCUS were created. The
parent-reported form included 59 items and the patient-reported
form included 58 items, in the domains of standing/walking,
grip/reach, sleeping, schooling, activities, eating/appetite, satis-
faction and botheredness with functional status, and treatment
satisfaction. Sixteen parents and 2 adult MPS II patients com-
pleted the questionnaire and provided feedback on relevance of
questions, understandability, and feasibility of use. Domains of
grip/reach, schooling, activities, satisfaction, and botheredness
with physical function achieved a Cronbach’s alpha of at least
0.84. Based on these analyses for construct validity along with
written and interview feedback, 16 items were revised for clarity
and speciﬁcity, 6 were removed, and 9 were added. CONCLU-
SIONS: Preliminary results suggest that the HS-FOCUS may be
useful for assessing functional health in MPS II. Inasmuch as
existing instruments do not adequately assess functional out-
comes in patients with MPS II, this preliminary version of the
HS-FOCUS may offer clinicians and researchers an opportunity
to do so. Future studies should validate the instrument.
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OBJECTIVES: To validate a new instrument, the Hunter 
Syndrome-Functional Outcomes for Clinical Understanding
Scale (HS-FOCUS), a new instrument for assessing functional
status in children and adolescents with Mucopolysaccharidosis
II (MPS II; Hunter syndrome [HS]), one of a group of rare
genetic, lysosomal storage diseases. METHODS: Following IRB
approval, participants were recruited from the 2003 Annual
MPS Family Conference and an ongoing MPS II Phase I/II clin-
ical trial. Eligible participants were individuals with MPS II at
least 12 years old or a parent of a child of any age with MPS II.
The instrument was administered twice over a 3-week period.
Face validity, internal reliability, domain intercorrelation, parent-
child correlations, and test-retest reliability were assessed for
each of six domains (standing/walking, grip/reach, sleeping,
schooling/work, activities, and breathing) and for the overall dis-
ability score. RESULTS: Eleven patients with MPS II and 27
parent caregivers of patients with MPS II completed the HS-
FOCUS. Face validity was conﬁrmed through interviews with
expert clinicians, patients with MPS II, and their families. The
instrument showed very good overall internal reliability (Cron-
bach’s alpha = 0.93 [parents] and 0.83 [patients]). The HS-
FOCUS showed good reproducibility (rs = 0.85, p < 0.0001
[parents] and 0.71, p = 0.031 [patients)] for overall function in
test-retest analyses, although sleeping and breathing domains
had weaker correlations. Intercorrelation coefﬁcients for each
domain with the overall functional disability score were strong
(range rs = 0.69 to 0.89). Weak correlations were reported
between the nine parent-child pairs, which is commonly accepted
as a challenge in survey research of children and adolescents.
CONCLUSIONS: Findings of this validation study suggest that
the HS-FOCUS may effectively capture disability and functional
status in individuals with MPS II. Additional assessment of sen-
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sitivity and construct validity are warranted, and could be con-
ducted as part of ongoing clinical trials.
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)—Health Policy Studies
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OBJECTIVE: Immunomodulatory drugs have provided hope to
patients with MS. The Nova Scotia provincial health ministry
funds these drugs for patients who are seen by the Dalhousie
Multiple Sclerosis Research Unit (DMSRU), meet predeﬁned 
criteria and attend an education clinic. This study examined the
utilization of these drugs under the provincial program.
METHODS: Data from the DMSRU and pharmacy dispensing
records was accessed from July 1, 1998 to September 16, 2003.
2035 patients attended the clinic of whom 1819 were diagnosed
with MS. Patient and drug therapy characteristics were deter-
mined and compared in those patients receiving immunomodu-
latory drug therapy and those who were not. RESULTS: A total
of 433 patients (326 F) received immunomodulatory drug
therapy. Fifty-nine percent of patients were between 35 and 49
years of age and 56% were classiﬁed as relapsing remitting MS.
Funded patients increased from 98 in 1998 to 365 in 2002. In
2001 the median drug cost/patient was CDN $15,508. The
median number of prescriptions/year was 12.0 (mean 10.7 ±
3.3). 84% of patients received a prescription in 2 ﬁscal years,
while 17% received a prescription in all 5. In 2001, 60% of
patients had a maximum EDSS score of 5 or less. Patients receiv-
ing immunomodulatory drugs were less likely to have EDSS
scores over 6 compared to those not receiving these drugs. The
total expenditure for MS drugs was $4.96 million in 2001/2 with
Rebif® accounting for $1.6 million (CDN). CONCLUSION:
Expenditures grew rapidly for the program (from $0.83 million
in 1998 to $4.96 million in 2001). Most patients were compli-
ant receiving 12 prescriptions/year. Further work is ongoing to
compare patient outcomes and health care costs in those patients
receiving therapy to those who are not.
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OBJECTIVES: The purpose of this study is to estimate the
number of physician visits for a primary complaint of insomnia
and characterize patients with a primary complaint of insomnia,
diagnosis of insomnia and patients utilizing sleep medications.
METHODS: Data was obtained from the 2001 version of the
National Ambulatory Medical Care Survey. Descriptive analyses
were utilized to examine individuals with a primary complaint
of insomnia and/or diagnosed with insomnia. Patient level
weights were utilized to derive national population estimates
from a representative sample. RESULTS: In 2001, there were 1.6
million patient visits for a primary complaint of insomnia. More
females than males (87% vs. 17%), and more Caucasians than
other races (64% vs. 36%) reported insomnia as their primary
complaint. While only 22% of patients complaining of insom-
nia were diagnosed with a sleep disorder, a signiﬁcant number
(79%) were prescribed a medication, including Ambien or
Sonata (26%) and Benadryl (10%). During the same year, 4.8
million patients were diagnosed with a sleep disorder. Patients
were diagnosed by generalist (67%), Psychiatrist (3%) and other
specialist (43%). Yet, only 9% of patients diagnosed with a sleep
disorder had a primary complaint of insomnia upon visiting their
physician. Medications were utilized by 76% of these patients
including Ambien or Sonata (15%) and Benadryl (3%). Only
15% of patients using Ambien or Sonata and only 4% of patients
taking Benadryl were diagnosed with a sleep disorder. CON-
CLUSIONS: This work describes the characteristics of patients
with a primary complaint of insomnia and their resultant diag-
nosis and pharmaceutical treatment. Additionally, we look at
patients diagnosed with insomnia and describe the most common
patient reported reason for their visit and their pharmaceutical
treatment.
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)—Methods
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THE SENSITIVITY OF COST-EFFECTIVENESS ESTIMATES IN
MULTIPLE SCLEROSIS TO INTERNATIONAL DIFFERENCES IN
NATURAL HISTORY: SWEDEN VERSUS NOVA SCOTIA,
CANADA
Skedgel CD, Brown MG, MacKinnon-Cameron D
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OBJECTIVE: To investigate the sensitivity of cost-effectiveness
(CE) estimates of drug treatment that delays disability progres-
sion in Multiple Sclerosis (MS) to international differences in the
underlying natural history of the disease. METHODS: Simula-
tion model Multiple Sclerosis PharmacoEvaluation Tool (MS-
PEET) was developed to estimate the CE of drug treatment that
delays disability progression in Multiple Sclerosis. MS-PEET was
initially populated with Swedish data on the natural history of
disability progression, measured by the cumulative probability
of patients reaching three disease-speciﬁc severity endpoints
(EDSS 3, 6, 10). Treatment effectiveness is modeled as a reduc-
tion in the probability of EDSS progression. This analysis com-
pares CE estimates based on Nova Scotia natural history data
with estimates based on Swedish data, holding all other variables
constant. Nova Scotia natural history data is from the Dalhousie
Multiple Sclerosis Research Unit (DMSRU). The DMSRU has up
to 25 years of clinical follow-up for 2368 patients. RESULTS:
Preliminary analysis of untreated patients in DMSRU data shows
a less severe natural history course in Nova Scotia relative to
Sweden. The reported cumulative probability of progressing to
severe disability (EDSS ≥ 6) within 10 years of MS-onset is
almost 60 percent less in Nova Scotia than in Sweden. CE esti-
mates based on Nova Scotia natural history data are roughly 
150 percent higher than estimates based on Swedish data. 
CONCLUSION: A less severe MS natural history course limits
potential gains in terms of disability years avoided with treat-
ment. Consequently estimates of cost-effectiveness are likely to
be sensitive to differences in the underlying natural history. MS-
